RxSight (RXST) Cash from Operations Growth (1y) (2021 - 2026)
RxSight (RXST) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | -12.60% |
| 10 | RxSight | 250.40 Mn | -153.85 Mn | - | -117.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.96% |
| Mar 31, 2026 | -23.31% |
| Dec 31, 2025 | 73.80% |
| Sep 30, 2025 | -282.62% |
| Jun 30, 2025 | -8.67% |
| Mar 31, 2025 | 5.12% |
| Dec 31, 2024 | 48.68% |
| Sep 30, 2024 | 108.14% |
| Jun 30, 2024 | 46.63% |
| Mar 31, 2024 | 47.60% |
| Dec 31, 2023 | 40.08% |
| Sep 30, 2023 | 47.45% |
| Jun 30, 2023 | 49.09% |
| Mar 31, 2023 | -18.55% |
| Dec 31, 2022 | -58.84% |
| Sep 30, 2022 | -10.42% |
| Jun 30, 2022 | -23.74% |
| Mar 31, 2022 | -46.17% |
| Dec 31, 2021 | -6.02% |
| Sep 30, 2021 | -97.97% |